Managing the Bleeding Patient
At the conclusion of this presentation the participants will be able to:
- Describe the coagulation cascade
- Describe the most relevant types of hemophilia
- Describe the difference between clotting and chromogenic methods
- Describe the effects that extended half-life (e.g., rFVIII and rFIX) products have on aPTT reagents
- Identify the targets of the extended half-life products for rFVIII (Emicizumab (Hemlibra))
Specially Curated for Laboratorians and offering PACE continuing education credits
- Bleeding
- Emicizumab
- Hemophilia
- Mechanical Circulatory Support
- hemophilia therapy
- PFA
- Extended half life products
- PACE
- CEU
- Continuing Ed
